Silver Book Fact

Delaying the onset of Alzheimer’s by only 5 years could reduce the number of people with Alzheimer’s by almost 50% after 50 years.

Brookmeyer, Ronald, Sarah M. Gray, and Claudia H. Kawas. Projections of Alzheimer’s Disease in the United States and the Public Health Impact of Delaying Disease Onset. Am J Public Health. 1998; 88(9): 1337-42. http://www.ajph.org/cgi/content/abstract/88/9/1337?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=brookmeyer&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Reference

Title
Projections of Alzheimer’s Disease in the United States and the Public Health Impact of Delaying Disease Onset
Publication
Am J Public Health
Publication Date
1998
Authors
Brookmeyer, Ronald, Sarah M. Gray, and Claudia H. Kawas
Volume & Issue
Volume 88, Issue 9
Pages
1337-42
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Out-of-Pocket Costs, Slowed Progression  
  • Around 75 – 100 experimental therapies that are aimed at slowing or stopping the progression of Alzheimer’s disease are currently in clinical trials.  
  • Deep brain stimulation, an electrical signal delivered deep inside the brain, provides significant symptomatic relief for Parkinson’s patients whose medication is no longer effective.  
  • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.  
  • Average Annual Direct Medical Costs Per Person with Parkinson’s Disease